Last reviewed · How we verify
MPV-ACYW135 Vaccine Group
MPV-ACYW135 is a meningococcal polysaccharide conjugate vaccine that stimulates immune responses against serogroups A, C, Y, and W-135 of Neisseria meningitidis.
MPV-ACYW135 is a meningococcal polysaccharide conjugate vaccine that stimulates immune responses against serogroups A, C, Y, and W-135 of Neisseria meningitidis. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.
At a glance
| Generic name | MPV-ACYW135 Vaccine Group |
|---|---|
| Also known as | Group A, C, Y and W-135 Meningococcal Polysaccharide Vaccine |
| Sponsor | Beijing Minhai Biotechnology Co., Ltd |
| Drug class | Meningococcal conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains polysaccharide antigens from four meningococcal serogroups conjugated to a protein carrier, which enhances immunogenicity and T-cell dependent responses. This conjugate approach promotes both antibody production and cellular immunity to provide protection against invasive meningococcal disease caused by these serogroups.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135
Common side effects
- Injection site pain/erythema
- Fever
- Myalgia
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MPV-ACYW135 Vaccine Group CI brief — competitive landscape report
- MPV-ACYW135 Vaccine Group updates RSS · CI watch RSS
- Beijing Minhai Biotechnology Co., Ltd portfolio CI